Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer
921 Hybrid lipid nanoparticles enable in situ and ex vivo dendritic cell-based cancer immunotherapy
- 11Massachusetts General Hospital, Boston, MA, USA
- 2University of Houston, Houston, TX, USA
- 3Massachusetts General Hospital, Boston, MA, USA
Related
- Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting
- Dendritic cell centric nanoengineering couples antigen acquisition and STING activation for cancer immunotherapy
- Targeting Dendritic Cells in Cancer Immunotherapy: From Immune Priming to Tumor Microenvironment Reprogramming
- PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy
- Immune-evading universal donor iPSC-derived natural killer cells enable off-the-shelf cancer immunotherapy
BibTeX
@article{weissleder2026hybrid,
title = {{921 Hybrid lipid nanoparticles enable in situ and ex vivo dendritic cell-based cancer immunotherapy}},
author = {Ralph Weissleder and Riddha Das and Christopher S Garris},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-sitc2026.0921},
url = {https://doi.org/10.1136/jitc-2026-sitc2026.0921},
note = {CC BY},
}
RIS
TY - JOUR
TI - 921 Hybrid lipid nanoparticles enable in situ and ex vivo dendritic cell-based cancer immunotherapy
AU - Ralph Weissleder
AU - Riddha Das
AU - Christopher S Garris
PY - 2026
DA - 2026/11/06
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-sitc2026.0921
UR - https://doi.org/10.1136/jitc-2026-sitc2026.0921
SN - 2051-1426
ER -